AU2019215802A1 - Oral formulations and uses thereof - Google Patents

Oral formulations and uses thereof Download PDF

Info

Publication number
AU2019215802A1
AU2019215802A1 AU2019215802A AU2019215802A AU2019215802A1 AU 2019215802 A1 AU2019215802 A1 AU 2019215802A1 AU 2019215802 A AU2019215802 A AU 2019215802A AU 2019215802 A AU2019215802 A AU 2019215802A AU 2019215802 A1 AU2019215802 A1 AU 2019215802A1
Authority
AU
Australia
Prior art keywords
composition
total weight
sodium
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019215802A
Other languages
English (en)
Inventor
Andreea SASARMAN
Pierre Vankan
Grasiela Bourscheit WILLMBRINK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eustralis Pharmaceuticals Ltd
Original Assignee
Eustralis Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900324A external-priority patent/AU2018900324A0/en
Application filed by Eustralis Pharmaceuticals Ltd filed Critical Eustralis Pharmaceuticals Ltd
Publication of AU2019215802A1 publication Critical patent/AU2019215802A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019215802A 2018-02-02 2019-02-01 Oral formulations and uses thereof Abandoned AU2019215802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900324 2018-02-02
AU2018900324A AU2018900324A0 (en) 2018-02-02 Oral Formulations and Uses Thereof
PCT/AU2019/050076 WO2019148247A1 (en) 2018-02-02 2019-02-01 Oral formulations and uses thereof

Publications (1)

Publication Number Publication Date
AU2019215802A1 true AU2019215802A1 (en) 2020-07-23

Family

ID=67477795

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019215802A Abandoned AU2019215802A1 (en) 2018-02-02 2019-02-01 Oral formulations and uses thereof

Country Status (9)

Country Link
US (1) US20200368166A1 (enExample)
EP (1) EP3746078A4 (enExample)
JP (1) JP2021512869A (enExample)
CN (1) CN111670035A (enExample)
AU (1) AU2019215802A1 (enExample)
CA (1) CA3089656A1 (enExample)
MX (1) MX2020008137A (enExample)
WO (1) WO2019148247A1 (enExample)
ZA (1) ZA202005143B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746077A4 (en) 2018-02-02 2021-10-27 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) PARENTERAL FORMULATIONS AND THEIR USES
US12351557B2 (en) 2018-12-24 2025-07-08 Eustralis Pharmaceuticals Limited Chemical compound manufacture, new salt form, and therapeutic uses thereof
WO2021035289A1 (en) * 2019-08-23 2021-03-04 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic methods and uses thereof
CN118217314A (zh) * 2020-09-30 2024-06-21 杭州远大生物制药有限公司 微生物制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
US20100184819A1 (en) * 2007-07-19 2010-07-22 Robert Vink Method for reducing intracranial pressure
US8454993B2 (en) * 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
LT2722045T (lt) * 2009-11-18 2016-09-26 Helsinn Healthcare Sa Kompozicija skirta gydyti centralizuotai kontroliuojamą pykinimą ir vėmimą
IN2013MU02031A (enExample) * 2013-06-14 2015-06-05 Novoexcipients Pvt Ltd
RU2674653C2 (ru) * 2013-07-02 2018-12-12 Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
RU2718044C2 (ru) * 2013-11-12 2020-03-30 Вертекс Фармасьютикалз Инкорпорейтед Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
KR20160068975A (ko) * 2013-12-03 2016-06-15 에프. 호프만-라 로슈 아게 약학 조성물

Also Published As

Publication number Publication date
EP3746078A4 (en) 2021-11-17
US20200368166A1 (en) 2020-11-26
MX2020008137A (es) 2020-10-19
EP3746078A1 (en) 2020-12-09
JP2021512869A (ja) 2021-05-20
CN111670035A (zh) 2020-09-15
CA3089656A1 (en) 2019-08-08
WO2019148247A1 (en) 2019-08-08
ZA202005143B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
JP5274261B2 (ja) 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
TWI428151B (zh) 含有甘露醇或乳糖之固形製劑
JP4260370B2 (ja) 塩酸ファスジルの経口徐放性製剤
AU2019280026B2 (en) Galenic formulations of organic compounds
TWI488657B (zh) 貯藏安定性經改善之醫藥組成物及改善醫藥組成物之貯藏安定性的方法
AU2019215802A1 (en) Oral formulations and uses thereof
US11279682B2 (en) Vortioxetine pyroglutamate
EP2646434B1 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
DK2802311T3 (en) SUBLINGUAL PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIHISTAMIN MEDICINE AND PROCEDURE FOR PREPARING THEREOF
US5158776A (en) Solid oral dosage forms of ifosfamide
KR20160030093A (ko) 구강 내 붕괴정
WO2020111089A1 (ja) 医薬組成物
JP7665531B2 (ja) ピロールカルボキサミドを含む口腔内崩壊錠
US11648242B2 (en) Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
US20100272800A1 (en) Orally disintegrating olanzapine tablet
KR20150096787A (ko) Ｎ-[5-[2-(3,5-디메톡시페닐)에틸]-2ｈ-피라졸-3-일]-4-[(3ｒ,5ｓ)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제
EP2441438A1 (en) Sachet formulations of eslicarbazepine
JP2021104974A (ja) フェブキソスタット製剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application